Last reviewed · How we verify
NCT05273541
Safety and Immunogenicity of Prime-boost Vaccination of SARS-CoV-2 in Patients With Cancer
Phase 1, PHASE2 trial testing Coronavirus vaccination in Patients With Cancer in 100 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Beijing 302 Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 11 February 2022 |
| Primary completion | 30 December 2022 |
| Estimated completion | 30 July 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- Coronavirus vaccination — full drug profile →
Conditions studied
- Patients With Cancer — all drugs for Patients With Cancer →
- Vaccine Reaction — all drugs for Vaccine Reaction →
- COVID-19 — all drugs for COVID-19 →
Sponsor
Beijing 302 Hospital
Who can join
Adults 18 to 70, any sex, with Patients With Cancer or Vaccine Reaction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic since late 2019 that resulted in more than 360 million population infection. Patients with cancers may be at higher risk of infection and severity than those without cancer. Mass vaccination has been carried out, but reinfection and vaccine breakthrough cases still occur. Now, the prime-boost regimen was identified safe and efficient, but the reactogenicity and immunogenicity of prime-boost vaccine strategy in cancer patients were not known.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Cancer Patients and the COVID-19 Vaccines: Considerations and Challenges.
Almasri M, Bshesh K, Khan W, Mushannen M, et al · · 2022 · cited 9× · PMID 36428722 · DOI 10.3390/cancers14225630
Verify or expand the search:
- PubMed search for NCT05273541
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Beijing 302 Hospital trials
Trials by the same sponsor.
- NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
- NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
- NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
- NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
- NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05273541 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
- Last refreshed: 18 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05273541.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing